Inventiva S.A. Form 6-K Summary
Business Context and Reporting Period
Inventiva S.A., a French biopharmaceutical company, filed this Form 6-K for January 2023. The filing reports the publication of a second notice for the company’s Ordinary and Extraordinary General Meeting.
Meeting and Corporate Action
- The second notice was published on January 6, 2023; the initial notice was published on December 19, 2022.
- The General Meeting is scheduled for January 25, 2023, at 2:00 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon, France.
- A copy of the second notice is furnished as Exhibit 99.1.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance metrics.
Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, operational outlook, risk updates, contingencies, or unusual financial items. The principal disclosed event is the scheduled shareholder meeting.
Important Facts to Verify
- Review Exhibit 99.1 for the full agenda, resolutions, voting procedures, and any proposed corporate actions.
- Verify whether the General Meeting occurred on January 25, 2023 and review the resulting resolutions.
- Consult subsequent filings for any financing, governance, or strategic developments associated with the meeting.